通过皮肤冠状动脉干预后对心力衰竭的Huoxin药丸的有效性和机制:双盲,随机,安慰剂控制并行试验的研究方案
Bo-Yong Qiu1, Bai-Rong Xu1, Yan-Kun Song1
1Heart Center/National Regional (Traditional Chinese Mdicine) Cardiovascular Diagnosis and Treatment Center, The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, China.
Contemporary clinical trials communications
|July 19, 2024
概括
这项临床试验调查了通过皮肤冠状动脉干预 (PCI) 后心力衰竭 (HF) 的Huoxin药片 (HXP). 多omics分析将探索HXP的研究.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
- 蛋白质组学是指蛋白质组学.
- 代谢学 代谢学 代谢学
背景情况:
- 冠心病 (CHD) 是全球心血管疾病的主要原因.
- 心脏重塑是心脏衰竭 (HF) 在心脏病后进展的关键病理过程.
- 现有的高血压治疗方法往往缺乏全面的证据,特别是来自传统中医的药物,如Huoxin药丸 (HXP).
研究的目的:
- 评估Huoxin药片 (HXP) 在经皮冠状动脉干预 (PCI) 后治疗心力衰竭 (HF) 的疗效.
- 阐明HXP在减轻心脏重塑中的潜在机制,使用多omics技术.
- 为使用HXP在治疗CHD和HF方面提供基于证据的支持.
主要方法:
- 一项随机,双盲,安慰剂对照试验,涉及60名接受PCI的HF患者.
- 参与者将接受传统治疗加HXP或安慰剂.
- 结果包括NYHA心脏功能等级,李的HF得分,运动耐受性,生活质量,心脏超声波,心电图和生物化学标记.
主要成果:
- 该部分将在研究完成后填写.
结论:
- 这项研究旨在确定HXP作为PCI后HF的潜在治疗选择.
- 预计这些发现将为HXP对心脏重塑的影响提供机械洞察力.
- 该试验可能有助于基于证据的传统中医在心血管保健中的整合.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents
563
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563
Heart Failure Drugs: Diuretics
361
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
361


